Mark,
I heard that one question from you. I'm sure it was
you because just a couple of days ago I heard you ask
exactly the same quesion. Am I right?
A couple of points about that interview on ROBTV.
She really can't comment publicly on FDA; but, she did
say (I forget the exact wording) that she was comfortable
with both North American submissions.
Last year I was hanging on every word too much and this
year I'm more interested in the fact that we're expanding
the plant at this time, about Acqua, about the WF10 phase
III, about product launch, european timing - in other words
real events versus the words.
The words I did like though were related to market sizes.
For the first time I've heard what I consider a truer
estimate of the market now sized at $12 billion US.
And in conjunction with that she mentioned 10% where the
previous public statements were 5%.
Having stated in one interview the $12 billion and 10% any
new potential investor will come away saying, "OK, so
they're targeting $1.2 billion US in sales."
The second point is plant inspection. Whether or not there
had been a previous FDA inspection, the expanded facilities
would need to be inspected again and it would be the
expanded plan that would be submitted for final approval.
I saw no denial that they had been up. Only a proper
statement that Dimethaid was hoping the inspection was in
the near future (after the expansion is complete).
I'm not particularly focused on this. FDA brings a triple
digit stock price with it and as I've said so often, I have
100% confidence that Pennsaid will eventually be approved
everywhere it applies.
I like the fact we're expanding while taking little cash
from placements in.
One last point right now. We will be doing larger studies
down the road just as Celbrex and Vioxx did to improve our
labelling and definition as a medicine.
I like our chances when that's us up there a couple of years
from now getting premier acknowledgment that Pennsaid is
the safest NSAID with the full power of NSAID for over half
of all of the market.
That's the game plan in my opinion and after that, we're
talking COX2 type numbers and share price in the 200 plus,
plus range.
Get some rest Rebecca. This is a gruelling pace.
Wolf
PS - fungal product clinical trials may start this year. |
